MedTrace Logo

Diffusion-weighted Imaging Study in Cancer of the Ovary

NCT01505829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2020-01-23

No results posted yet for this study

Summary

This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response. This will involve standardising DW-MRI for the abdomen and pelvis across multiple centres and platforms, assessing reproducibility of the measurement in patients planned for neoadjuvant chemotherapy and assessing its utility as an early response biomarker in patients with platinum-sensitive relapse due to receive therapy with carboplatin. Scanning measurements will be correlated with histopathological markers in tumour samples in order to link the biomarker with response mechanisms.

Conditions

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Royal Marsden NHS Foundation Trust

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • Northumbria Healthcare NHS Foundation Trust

    collaborator OTHER

  • East and North Hertfordshire NHS Trust

    collaborator OTHER_GOV

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Nandita deSouza, Professor · ICR

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-12-31
Completion
2018-10-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01505829 on ClinicalTrials.gov